[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

EP2015782A4 - Compositions and methods for modulating gene expression - Google Patents

Compositions and methods for modulating gene expression

Info

Publication number
EP2015782A4
EP2015782A4 EP07760600A EP07760600A EP2015782A4 EP 2015782 A4 EP2015782 A4 EP 2015782A4 EP 07760600 A EP07760600 A EP 07760600A EP 07760600 A EP07760600 A EP 07760600A EP 2015782 A4 EP2015782 A4 EP 2015782A4
Authority
EP
European Patent Office
Prior art keywords
compositions
methods
gene expression
modulating gene
modulating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP07760600A
Other languages
German (de)
French (fr)
Other versions
EP2015782A2 (en
Inventor
Dusan Stanojevic
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Crosslink Genetics Corp
Original Assignee
Crosslink Genetics Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Crosslink Genetics Corp filed Critical Crosslink Genetics Corp
Publication of EP2015782A2 publication Critical patent/EP2015782A2/en
Publication of EP2015782A4 publication Critical patent/EP2015782A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111General methods applicable to biologically active non-coding nucleic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/11Antisense
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/15Nucleic acids forming more than 2 strands, e.g. TFOs
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/35Nature of the modification
    • C12N2310/351Conjugate
    • C12N2310/3513Protein; Peptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
EP07760600A 2006-04-12 2007-04-12 Compositions and methods for modulating gene expression Withdrawn EP2015782A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US79130506P 2006-04-12 2006-04-12
PCT/US2007/066571 WO2007121326A2 (en) 2006-04-12 2007-04-12 Compositions and methods for modulating gene expression

Publications (2)

Publication Number Publication Date
EP2015782A2 EP2015782A2 (en) 2009-01-21
EP2015782A4 true EP2015782A4 (en) 2010-04-07

Family

ID=38610393

Family Applications (1)

Application Number Title Priority Date Filing Date
EP07760600A Withdrawn EP2015782A4 (en) 2006-04-12 2007-04-12 Compositions and methods for modulating gene expression

Country Status (3)

Country Link
EP (1) EP2015782A4 (en)
CA (1) CA2649114A1 (en)
WO (1) WO2007121326A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2784829T3 (en) 2009-04-08 2020-10-01 Faulstich Heinz Dr Amatoxin-provided therapeutic cell surface-binding components designed for tumor therapy
ES2402254T3 (en) * 2010-09-30 2013-04-30 Heidelberg Pharma Ag Amatoxin conjugates with improved linkers
US9815877B2 (en) 2012-06-07 2017-11-14 The Children's Hospital Of Philadelphia Controlled gene expression methods
EP2774624A1 (en) * 2013-03-04 2014-09-10 Heidelberg Pharma GmbH Amatoxin derivatives
JP6321687B2 (en) * 2014-03-10 2018-05-09 ハイデルベルク ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング Amatoxin derivatives
IL303455A (en) 2016-06-17 2023-08-01 Crispr Therapeutics Ag Compositions and methods for the depletion of cd117+cells
EP3738608A4 (en) * 2017-08-18 2021-12-08 Sichuan Baili Pharm Co. Ltd Non-natural amatoxin-type antibody conjugate
WO2024036143A2 (en) * 2022-08-09 2024-02-15 Ptc Therapeutics, Inc. Methods for modulating rna splicing

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030105045A1 (en) * 2000-10-13 2003-06-05 Crosslink Genetics Corporation Artificial transcriptional factors and methods of use

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030105045A1 (en) * 2000-10-13 2003-06-05 Crosslink Genetics Corporation Artificial transcriptional factors and methods of use

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
ANSARI A Z ET AL: "TOWARDS A MINIMAL MOTIF FOR ARTIFICIAL TRANSCRIPTIONAL ACTIVATORS", CHEMISTRY AND BIOLOGY, CURRENT BIOLOGY, LONDON, GB, vol. 8, no. 6, 1 January 2001 (2001-01-01), pages 583 - 592, XP001031162, ISSN: 1074-5521 *
ARORA PARAMJIT S ET AL: "Design of artificial transcriptional activators with rigid poly-L-proline linkers.", JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, vol. 124, no. 44, 6 November 2002 (2002-11-06), pages 13067 - 13071, XP007911805, ISSN: 0002-7863 *
INGLES C J ET AL: "ALPHA AMANITIN RESISTANCE OF RNA POLYMERASE II IN MUTANT CHINESE HAMSTER OVARY CELL LINES", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 251, no. 9, 1976, pages 2729 - 2734, XP007911801, ISSN: 0021-9258 *
KUZNETSOVA S ET AL: "Gene activation by triplex-forming oligonucleotide coupled to the activating domain of protein VP16", NUCLEIC ACIDS RESEARCH, OXFORD UNIVERSITY PRESS, SURREY, GB, vol. 27, no. 20, 15 October 1999 (1999-10-15), pages 3995 - 4000, XP002222219, ISSN: 0305-1048 *
KWON YOUNGJOO ET AL: "Small molecule transcription factor mimic", JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, vol. 126, no. 49, 15 December 2004 (2004-12-15), pages 15940 - 15941, XP007911804, ISSN: 0002-7863 *
STANOJEVIC D ET AL: "A highly potent artificial transcription factor", BIOCHEMISTRY, AMERICAN CHEMICAL SOCIETY, EASTON, PA.; US, vol. 41, no. 23, 11 June 2002 (2002-06-11), pages 7209 - 7216, XP002222221, ISSN: 0006-2960 *

Also Published As

Publication number Publication date
WO2007121326A2 (en) 2007-10-25
EP2015782A2 (en) 2009-01-21
CA2649114A1 (en) 2007-10-25
WO2007121326A3 (en) 2008-12-24

Similar Documents

Publication Publication Date Title
ZA200908481B (en) Compositions and methods for altering gene expression
IL250678A0 (en) Compositions and methods for inhibiting expression of the pcsk9 gene
EP2052085A4 (en) Methods for modulating set and uses thereof
IL195619A0 (en) Compositions and methods for joininig non-conjoined iumens
HK1137670A1 (en) Compositions and methods for arthrodetic procedures
IL194788A0 (en) Compositions and methods for modulating vascular development
EP2068875A4 (en) Compositions and methods for modulating sirtuin activity
EP2043696A4 (en) Methods and compositions for targeting gc1qr/p32
IL202184A0 (en) Methods and compositions for increased transgene expression
EP2066687A4 (en) Compositions and methods for inhibiting expression of the hamp gene
IL194814A0 (en) Mglur5 modulators i
PT2129680E (en) Combined hairpin-antisense compositions and methods for modulating expression
EP2101731A4 (en) Endoxifen methods and compositions
EP2235033A4 (en) Methods and compositions for increasing gene expression
ZA200807714B (en) Gene disruptions, compositions and methods relating thereto
EP2015782A4 (en) Compositions and methods for modulating gene expression
EP2088865A4 (en) Guggulphospholipid methods and compositions
AU2007291030A8 (en) Novel compositions and methods
ZA200808498B (en) Novel gene disruptions,compositions and methods relating thereto
EP2018443A4 (en) Compositions and methods for inhibiting expression of ikk-b gene
GB0610009D0 (en) Culture medium
EP2142672A4 (en) Compositions and methods for gene silencing
EP2132251A4 (en) Composition and method
GB0625208D0 (en) Composition and method
GB0600261D0 (en) Composition and method

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20081112

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR MK RS

R17D Deferred search report published (corrected)

Effective date: 20081224

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/00 20060101ALI20090120BHEP

Ipc: A61K 38/00 20060101ALI20090120BHEP

Ipc: C12Q 1/02 20060101ALI20090120BHEP

Ipc: C12Q 1/68 20060101AFI20090120BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20100304

17Q First examination report despatched

Effective date: 20100616

DAX Request for extension of the european patent (deleted)
RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: CROSSLINK GENETICS CORPORATION

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

INTG Intention to grant announced

Effective date: 20140325

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20140805